Skip to main content

Advertisement

SpringerLink
Log in

Autoinflammation in 2010

Expanding clinical spectrum and broadening therapeutic horizons

  • Year in Review
  • Published:

From Nature Reviews Rheumatology

View current issue Sign up to alerts

In 2010, important research into the systemic autoinflammatory diseases has confirmed and extended the role of IL-1 inhibition in hereditary autoinflammatory disorders, demonstrated a novel treatment for a dangerous complication, and expanded the spectrum of systemic autoinflammatory diseases while further implicating autoinflammation in the complications of the metabolic syndrome.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Kastner, D. L., Aksentijevich, I. & Goldbach-Mansky, R. Autoinflammatory disease reloaded: a clinical perspective. Cell 140, 784–790 (2010).

    Article  CAS  Google Scholar 

  2. Masters, S. L., Simon, A., Aksentijevich, I. & Kastner, D. L. Horror autoinflammaticus: the molecular pathology of autoinflammatory disease. Annu. Rev. Immunol. 27, 621–668 (2009).

    Article  CAS  Google Scholar 

  3. Neven, B. et al. Long-term efficacy of the interleukin-1 receptor antagonist anakinra in ten patients with neonatal-onset multisystem inflammatory disease/chronic infantile neurologic, cutaneous, articular syndrome. Arthritis Rheum. 62, 258–267 (2010).

    Article  CAS  Google Scholar 

  4. Lepore, L. et al. Follow-up and quality of life of patients with cryopyrin-asociated periodic syndromes treated with anakinra. J. Pediatr. 157, 310–315 (2010).

    Article  Google Scholar 

  5. Bodin, K. et al. Antibodies to human serum amyloid P component eliminate visceral amyloid deposits. Nature 468, 90–97 (2010).

    Article  Google Scholar 

  6. Duewell, P. et al. NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals. Nature 464, 1357–1361 (2010).

    Article  CAS  Google Scholar 

  7. Goldbach-Mansky, R. Blocking interleukin-1 in rheumatic diseases. Ann NY Acad. Sci. 1182, 111–123 (2009).

    Article  CAS  Google Scholar 

  8. Kubota, T. & Koike, R. Cryopyrin-associated periodic syndromes: background and therapeutics. Mod. Rheumatol. 20, 213–221 (2010).

    Article  Google Scholar 

  9. Lachmann, H. J. et al. Natural history and outcome in systemic AA amyloidosis. N. Engl. J. Med. 356, 2361–2371 (2007).

    Article  CAS  Google Scholar 

  10. Pepys, M. B. et al. Targeted pharmacological depletion of serum amyloid P component for treatment of human amyloidosis. Nature 417, 254–259 (2002).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Inflammatory Disease Section, Medical Genetics Branch, National Human Genome Research Institute, National Institutes of Health, 10 Center Drive, 10C101, Bethesda, 20892–1849, MD, USA

    Michael J. Ombrello & Daniel L. Kastner

Authors
  1. Michael J. Ombrello
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Daniel L. Kastner
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Michael J. Ombrello.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ombrello, M., Kastner, D. Expanding clinical spectrum and broadening therapeutic horizons. Nat Rev Rheumatol 7, 82–84 (2011). https://doi.org/10.1038/nrrheum.2010.229

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrrheum.2010.229

  • Springer Nature Limited

This article is cited by

Search

Navigation